3 Undervalued Pharmaceuticals Stocks for Thursday, June 20
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, June 20 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Monday, May 06
Discover the top 6 undervalued Pharmaceuticals stocks for Monday, May 06 based on AAII’s Stock Grades.Jenna Brashear
Is Bavarian Nordic A/S - ADR (BVNRY) Stock a Good Investment?
Learn more about Bavarian Nordic A/S - ADR's (BVNRY) stock grades for Momentum and Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | BVNRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,658.7 | $211.8 | 58% |
|
| Shares Out (Mil) | 12.6 | 55.4 | 24% |
|
| Institutional Ownership | 49.9% | 93.0% | 27% |
|
| Float (Mil) | 75.7 | 41.5 | 55% |
|
| Beta | 0.94 | 0.99 | 55% |
|
| Avg Daily Volume (000s) | 2 | 553 | 9% |
|
| Price Change (52-week) |
(6.1%) | 42.8% | 45% |
|
| Growth | BVNRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 26.4% | 13.2% | 87% |
|
| Net Income (5yr) | 36.5% | (10.3%) | 89% |
|
| EPS (5yr) | 27.0% | 15.8% | 78 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 48.9% | (15.7%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BVNRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $969 | $41 | 49% |
|
| Net Income (TTM) (Mil) | $236 | ($44) | 69% |
|
| EPS (TTM) | $2.971 | ($1.500) | 78% |
|
| Operating Cash Flow (TTM) (Mil) | $220 | ($35) | 60% |
|
| Net Cash Flow (TTM) (Mil) | ($67) | $-0 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $2,081 | $147 | 50% |
|
| Valuation | BVNRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.01 | na |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BVNRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 50.2% | 67.9% | 62% |
|
| Net Margin | 24.3% | (50.6%) | 83% |
|
| ROA | 10.6% | (47.4%) | 88% |
|
| ROE | 12.0% | (53.1%) | 62% |
|
| Liabilities to Assets | 10.2% | 29.7% | 6% |
|
| F-Score | na | 3 | na |
|
Bavarian Nordic A/S did not pass any screens on 11/13/2026.
